567 related articles for article (PubMed ID: 32660524)
1. High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies.
Yuan S; Liu Z; Xu Z; Liu J; Zhang J
J Hematol Oncol; 2020 Jul; 13(1):91. PubMed ID: 32660524
[TBL] [Abstract][Full Text] [Related]
2. High-mobility group box-1 in sterile inflammation.
Tsung A; Tohme S; Billiar TR
J Intern Med; 2014 Nov; 276(5):425-43. PubMed ID: 24935761
[TBL] [Abstract][Full Text] [Related]
3. HMGB1 in inflammation and cancer.
Wang S; Zhang Y
J Hematol Oncol; 2020 Aug; 13(1):116. PubMed ID: 32831115
[TBL] [Abstract][Full Text] [Related]
4. The hematopoietic stem-cell niche in health and leukemia.
Sánchez-Aguilera A; Méndez-Ferrer S
Cell Mol Life Sci; 2017 Feb; 74(4):579-590. PubMed ID: 27436341
[TBL] [Abstract][Full Text] [Related]
5. Microenvironmental regulation of hematopoietic stem cells and its implications in leukemogenesis.
Seshadri M; Qu CK
Curr Opin Hematol; 2016 Jul; 23(4):339-45. PubMed ID: 27071022
[TBL] [Abstract][Full Text] [Related]
6. Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2.
Zhang QY; Wu LQ; Zhang T; Han YF; Lin X
Oncol Rep; 2015 Apr; 33(4):1630-8. PubMed ID: 25652880
[TBL] [Abstract][Full Text] [Related]
7. Expression of the RET receptor tyrosine kinase and GDNFR-alpha in normal and leukemic human hematopoietic cells and stromal cells of the bone marrow microenvironment.
Gattei V; Celetti A; Cerrato A; Degan M; De Iuliis A; Rossi FM; Chiappetta G; Consales C; Improta S; Zagonel V; Aldinucci D; Agosti V; Santoro M; Vecchio G; Pinto A; Grieco M
Blood; 1997 Apr; 89(8):2925-37. PubMed ID: 9108413
[TBL] [Abstract][Full Text] [Related]
8. Neuroimmune/Hematopoietic Axis with Distinct Regulation by the High-Mobility Group Box 1 in Association with Tachykinin Peptides.
Gergues M; Nagula V; Bliss SA; Eljarrah A; Ayer S; Gnanavel N; Sinha G; Wu Q; Yehia G; Greco SJ; Qian J; Rameshwar P
J Immunol; 2020 Feb; 204(4):879-891. PubMed ID: 31924647
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations in the bone marrow microenvironment and dysregulated hematopoiesis.
Miller LH; Qu CK; Pauly M
Exp Hematol; 2018 Oct; 66():17-26. PubMed ID: 30076950
[TBL] [Abstract][Full Text] [Related]
10. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells.
Liu L; Yang M; Kang R; Wang Z; Zhao Y; Yu Y; Xie M; Yin X; Livesey KM; Lotze MT; Tang D; Cao L
Leukemia; 2011 Jan; 25(1):23-31. PubMed ID: 20927132
[TBL] [Abstract][Full Text] [Related]
11. Stromal abnormalities in neoplastic bone marrow diseases.
Dührsen U; Hossfeld DK
Ann Hematol; 1996 Aug; 73(2):53-70. PubMed ID: 8774614
[TBL] [Abstract][Full Text] [Related]
12. The role of high mobility group box 1 in innate immunity.
Lee SA; Kwak MS; Kim S; Shin JS
Yonsei Med J; 2014 Sep; 55(5):1165-76. PubMed ID: 25048472
[TBL] [Abstract][Full Text] [Related]
13. Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting.
Chiarini F; Lonetti A; Evangelisti C; Buontempo F; Orsini E; Evangelisti C; Cappellini A; Neri LM; McCubrey JA; Martelli AM
Biochim Biophys Acta; 2016 Mar; 1863(3):449-463. PubMed ID: 26334291
[TBL] [Abstract][Full Text] [Related]
14. The extracellular matrix: A key player in the pathogenesis of hematologic malignancies.
Sidhu I; Barwe SP; Gopalakrishnapillai A
Blood Rev; 2021 Jul; 48():100787. PubMed ID: 33317863
[TBL] [Abstract][Full Text] [Related]
15. Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression.
Angelopoulou E; Piperi C; Adamopoulos C; Papavassiliou AG
J Mol Med (Berl); 2016 Aug; 94(8):867-74. PubMed ID: 27262996
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic alteration of bone marrow HSC and microenvironmental association in experimentally induced leukemia.
Basak P; Chatterjee S; Das M; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
Curr Stem Cell Res Ther; 2010 Dec; 5(4):379-86. PubMed ID: 20528754
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplantation in hematologic malignancy.
Archuleta TD; Devetten MP; Armitage JO
Panminerva Med; 2004 Mar; 46(1):61-74. PubMed ID: 15238882
[TBL] [Abstract][Full Text] [Related]
18. High-mobility group box 1 (HMGB1) as a master regulator of innate immunity.
Castiglioni A; Canti V; Rovere-Querini P; Manfredi AA
Cell Tissue Res; 2011 Jan; 343(1):189-99. PubMed ID: 20835834
[TBL] [Abstract][Full Text] [Related]
19. Bone Marrow Micro-Environment in Normal and Deranged Hematopoiesis: Opportunities for Regenerative Medicine and Therapies.
Sarkaria SM; Decker M; Ding L
Bioessays; 2018 Mar; 40(3):. PubMed ID: 29384206
[TBL] [Abstract][Full Text] [Related]
20. Hematological malignancies: disease pathophysiology of leukemic stem cells.
Ramdass B; Chowdhary A; Koka PS
J Stem Cells; 2013; 8(3-4):151-87. PubMed ID: 24699024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
